F2G
ID: 3173293Oral antifungal therapy developer to treat life-threatening rare fungal infections
5
Funding Rounds
$302.6m
Money raised
Recent Funding Rounds
Overview
Oral antifungal therapy developer to treat life-threatening rare fungal infections
- Website:
- Business model: B2B
- Headquarters: Manchester
- Social accounts: linkedin
Unlock Complete Company Intelligence
Access comprehensive data and insights available only to Seedtable members
Financial Details
- • Complete funding history and valuations
- • Revenue estimates and financial metrics
- • Investment round details and terms
People & Contacts
- • Complete leadership team profiles
- • Contact information and email addresses
- • Board members and advisors
Market Intelligence
- • Competitive landscape analysis
- • Market position and growth metrics
- • Industry benchmarking data
Premium Tools
- • Export data and generate reports
- • Save companies to custom watchlists
- • API access for data integration
Join 10,000+ Professionals
Trusted by investors, founders, and analysts worldwide
Access detailed insights on 71,000+ companies worldwide
Funding
Funding series
Funding Series Analysis
The company F2G has raised a total of $302.55m in funding over 5 rounds.
Key Insights:
- F2G Series D Round, September 2024: $100m
- F2G August 2022 Funding Round: $70m
- F2G , August 2020: $60.8m
- F2G , June 2016: $60m
- F2G funding round, August 2008: $11.75m
Industries
F2G is active in the following industries: